secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001641172-25-018042
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq Panel grants Dermata Therapeutics exception until Aug 14, 2025 to meet minimum bid price rule
--------------------------------------------------------------------------------

- Company received Nasdaq delisting notice on May 14, 2025 for failing minimum $1.00 bid price over 30 consecutive days.
- Hearings Panel granted exception through August 14, 2025 to demonstrate compliance; suspension stayed during hearing process.
- Dermata will seek shareholder approval for reverse stock split at July 15, 2025 annual meeting to regain compliance.
- If compliance not achieved or other listing requirements unmet, common stock (DRMA) and warrants (DRMAW) may be delisted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225018042/0001641172-25-018042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000164117225018042/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer